Small-scale spatial variations of shortwave downward radiation

DWD/Meteorological Observatory Lindenberg is operating a small-scale ground- based network of measurement sites for precipitation and shortwave radiation. The area is located roughly 60 km southeast of Berlin city. 8 measurement sites are equipped with high quality instruments CM21/CM11 by Kipp & Zonen. The quality assessment routinely applied takes into account the basic astronomical and empirical considerations as well as some interdependencies like total to diffuse flux ratio and cross checking with sunshine duration. Possible shading due to growing vegetation is taken into account, too. This is complemented by an approach that is utilizing time-series of clear sky radiative transfer simulations for every site. For that purpose a link to cloud coverage obtained from Meteosat second generation geostationary satellite data, highly resolved in time and space, was established. The paper provides an overview of the surface radiation network and the current activities to improve automatic quality assessment using remotely sensed data and clear sky modelling. First evaluation efforts cover up to 12 years of data

Calixpyrroles, calixpyridinopyrroles and calixpyridines

The present invention provides calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles, having 4, 5, 6, 7, or 8 heterocyclic rings, as well as syntheses, derivatives, conjugates, multimers, and solid supports thereof. Such macrocycles have proved to be effective and selective ion- and neutral molecule-binding agents forming supramolecular ensembles, and ion- and neutral molecule-separation agents. The macrocycles are fully meso-non-hydrogen-substituted porphyrinogens, a few molecules of which were previously known but not recognized as possessing anion- or molecule-binding properties. The binding mode is noncovalent, primarily that of hydrogen-bonding, thereby providing a new mode for liquid chromatography, that of Hydrogen Bonding Liquid Chromatography. Further useful applications of the macrocycles provided herein include environmental remediation by removal of undesired ions or neutral molecules, and removal of phosphate for kidney dialysis.Board of Regents, University of Texas Syste

Cytokine expression by CD163+ monocytes in healthy and Actinobacillus pleuropneumoniae-infected pigs

Distinct monocyte subpopulations have been previously described in healthy pigs and pigs experimentally infected with Actinobacillus pleuropneumoniae (APP). The CD163+ subpopulation of bone marrow (BM), peripheral blood (PB) and lung monocytes was found to play an important role in the inflammatory process. The inflammation is accompanied by elevation of inflammatory cytokines. The aim of the study was to evaluate the contribution of CD163+ monocytes and macrophages to cytokine production during APP-induced lung inflammation. Cytokine production was assessed by flow cytometry (FC) and quantitative PCR (qPCR) in CD163+ monocytes and by qPCR, immunohistochemistry/fluorescence in lungs and tracheobronchial lymph nodes (TBLN). Despite the systemic inflammatory response after APP infection, BM and PB CD163+ monocytes did not express elevated levels of a wide range of cytokines compared to control pigs. In contrast, significant amounts of IL-1β, IL-6, IL-8 and TNF-α were produced in lung lesions and IL-1β in the TBLN. At the protein level, TNF-α was expressed by both CD163+ monocytes and macrophages in lung lesions, whereas IL-1β, IL-6 and IL-8 expression was found only in CD163+ monocytes; no CD163+ macrophages were found to produce these cytokines. Furthermore, the quantification of CD163+ monocytes expressing the two cytokines IL-1β and IL-8 that were most elevated was performed. In lung lesions, 36.5% IL-1β positive CD163+ monocytes but only 18.3% IL-8 positive CD163+ monocytes were found. In conclusion, PB and BM CD163+ monocytes do not appear to contribute to the elevated cytokine levels in plasma. On the other hand, CD163+ monocytes contribute to inflammatory cytokine expression, especially IL-1β at the site of inflammation during the inflammatory process.Peer reviewe

Interseasonal RSV infections in Switzerland - rapid establishment of a clinician-led national reporting system (RSV EpiCH).

In anticipation of an interseasonal respiratory syncytial virus (RSV) epidemic, a clinician-led reporting system was rapidly established to capture RSV infections in Swiss hospitals, starting in January 2021. Here, we present details of the reporting system and first results to June 2021. An unusual epidemiology was observed with an interseasonal surge of RSV infections associated with COVID-19-related non-pharmacological interventions. These data allowed real-time adjustment of RSV prophylaxis guidelines and consequently underscore the need for and continuation of systematic nationwide RSV surveillance

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known

Hybridní střešní panely pro noční chlazení a využívání solární energie v budovách

The aim of this contribution is to evaluate the usability of solar hybrid panels, which were originally optimized for heat load removal from buildings by radiation against the night sky, for water preheating. First we created a surrogate model based on CFD simulations defining performance of the panel dependent on changing boundary conditions. This model was then implemented to the water heating model created in TRNSYS software. Estimated hot water usage would suffice for operation of 2 restaurant facilities in a building of our interest. Subsequent simulations were carried out using reference year climate data for Brno (Central Europe). Results demonstrated that in the given conditions, the average annual efficiency of solar energy usage is 55%. The results also showed that the system is able to cover approximately 7% of the heat demand for water heating.Cílem příspěvku je vyhodnotit využitelnost hybridních solárních panelů, původně optimalizovaných pro odvod tepelné zátěže budov tepelným sáláním proti noční obloze, pro předehřev teplé vody

Dermatology outpatient population profiling: Indigenous and non-indigenous dermatoepidemiology

Background:  Little is known about the population using Australian dermatology outpatient services, in particular, Indigenous patients. This information is important to direct the strategic planning of dermatology services. Methods: This study is a multicentre, retrospective audit of all patients attending public, outpatient dermatology clinics over 7 months across four Perth tertiary hospitals. The patient population (4873 patients) was profiled by age, gender, Indigenous status and rural/urban status. Medical records of the Indigenous patient population (104 patients) were reviewed to reveal the most common skin conditions. Results:  The population using public, outpatient services had a median age of 48 years, 51.4% were male and 13.6% were from rural areas. Male patient median age was 50 years compared to 45 years for female patients (P = 0.002). Indigenous patients had a median age of 22 years, a female to male ratio of 3:2 and 26.9% were from rural areas. Over 50% of Indigenous patient appointments were missed. Skin infections, eczematous conditions and naevi were the most common skin conditions in Indigenous patients. Conclusions:  This data can guide strategies towards improving the provision of dermatology services for the Australian population. Particular attention is required towards improving Indigenous Australians' capacity to access dermatology services